Although a high standard of clinical practice and postgraduate training in intensive care medicine has long been achieved, an escalation of related research from Australia and New Zealand to international prominence is a much more recent phenomenon.
While many factors and individuals have been part of this expansion, two organisations have played particularly important roles in promoting and facilitating this maturation.
The Intensive Care Foundation (ICF) was established by the Australian and New Zealand Intensive Care Society (ANZICS) in 1990 to raise funds to support intensive care medicine research. With corporate sponsorship, a program of public fundraising and prudent investment, the ICF has grown to become a significant financier of both basic and clinical research.
In the last five years, the ICF has raised over $3,200,000 and awarded over $1,000,000 in research grants to more than 40 projects, including a number of studies developed through the ANZICS Clinical Trials Group (CTG). The ICF maintains around $2,000,000 in a range of carefully managed interestbearing investments. Current fundraising strategies are directed towards the general community, the corporate world and the intensive care community. A corporate function held late last year in Sydney raised around $100,000 and a similar function is planned for May this year.
Though originally conceived as a direct offshoot of ANZICS, the ICF has recently endeavoured to engage with the Intensive Care community more broadly, and now has established links with both the Joint Faculty of Intensive Care Medicine and the Australian College of Critical Care Nursing. A group of medical companies contribute funds that cover the running costs of the ICF, so that virtually all publicly raised funds can be directed towards either the growth fund or current research projects.
The ANZICS CTG was established 1994. Its principal aims are to conduct high-quality, collaborative clinical trials directed at improving patient-centred outcomes and to promote research in intensive care medicine in Australia and New Zealand. The focus of the CTG is to conduct investigator-initiated studies, independent of commercial influence, primarily to address clinically relevant questions. This was exemplified by the publication of the Dopamine Study in 2000 1 . This highly cited study has become a landmark intensive care medicine manuscript, and provided the ideal platform for the emerging CTG to conduct further large-scale trials. In addition, a bi-national strategy was launched by ANZICS and the Intensive Care Foundation in 1996 to develop a research and fundraising strategy. Four key research areas were identified resulting from key publications from the CTG in lung injury 2 , traumatic brain injury 3 , sepsis 4 and prevention of critical illness 5 .
A major milestone in the development of the CTG was the publication of the Saline vs. Albumin Fluid Evaluation (SAFE) Study 6 . This study was a collaboration between the CTG (including 16 ICUs in Australia and New Zealand), the George Institute for International Health and the Australian Red Cross Blood Service. The study was described "not only as a landmark trial, but a milestone in the discipline of Critical Care Medicine" 7 . Other key collaborative initiatives underway include the large interventional trials in glycaemic control, dosage of renal replacement therapy, nutrition strategies and decompressive craniectomy in traumatic brain injury. To date, the CTG has secured sequential competitive funding from the NHMRC and other major funding bodies, including the ICF in excess of A$15M.
As a result of many of the successes outlined above, the CTG was awarded a NHMRC enabling grant in 2006 to establish a research methods centre (the ANZIC Research Centre) based at the Monash University Department of Epidemiology and Preventive Medicine. This centre will be an integral component on future research outputs of the CTG for the next five years.
Towards the development of a robust fundraising organisation for intensive care, the ICF and the CTG have served this region well. Whilst each organisation is independent of the other, there is a high level of mutual support and open communication between them. The ICF has provided essential start-up or top-up funding for several major CTG projects, as well as funding for smaller projects, including those Editorial The maturation of academic Intensive Care Medicine in Australia and New Zealand: Time to capitalise on progress performed by young investigators, who are the CTG leaders of the future. The ICF also makes use of the success of CTG projects to promote intensive care research in the lay media, raising the profile of intensive care medicine.
For the future of Intensive Care research in Australia and New Zealand to be assured, it is vital that the intensive care medicine community actively support all aspects of both the CTG and the ICF in these complementary roles. This is imperative to capitalise on the remarkable progress achieved to date.
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